Expression of androgen receptors in triple negative breast carcinomas

Acta Histochemica

Volumn 115, Issue 4, 2013, Pages 344-348

  Mrklić, Ivana ^a   Pogorelić, Zenon ^a   Ćapkun, Vesna ^a   Tomić, SnjeŽana ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Androgen receptors; Basal like breast cancer; Prognosis; Survival analysis; Triple negative breast cancer

Indexed keywords

ANDROGEN RECEPTOR; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876304628     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2012.09.006     Document Type: Article

References (36)

1. Agoff S.N., Swanson P.E., Linden H., Hawes S.E., Lawton T.J. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003, 120:725-731.
2. Birell S.N., Hall R.E., Tilley W.D. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998, 3:95-103.
3. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334.
4. Cho L.C., Hsu Y.H. Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast. Kaohsiung J Med Sci 2008, 24:227-232.
5. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103:1656-1664.
6. Efron B., Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986, 1:54-75.
7. Ellis I.O., Schnitt S.J., Sastre-Garau X., Bussolati G., Tavassoli F.A., Eusebi V., et al. Invasive breast carcinoma. World Health Organisation classification of tumours. Pathology, genetics of tumours of the breast, female genital organs 2003, 13-48. IARC Press, Lyon. F.A. Tavassoli, P. Devilee (Eds.).
8. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
9. Fulford L.G., Reis-Filho J.S., Ryder K., Jones C., Gillett C.E., Hanby A., et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007, 9:R4.
10. Garay J.P., Karakas B., Abukhdeir A.M., Cosgrove D.P., Gustin J.P., Higgins M.J., et al. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res 2012, 9:14.
11. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 1997, 193:753-758.
12. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple-negative breast cancer - current status and future directions. Ann Oncol 2009, 20:1913-1927.
13. Gonzalez L.O., Corte M.D., Vazquez J., Junquera S., Sanchez R., Alvarez A.C., et al. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008, 8:149.
14. Hammond M.E., Hayes D.F., Wolff A.C., Mangu P.B., Temin S. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 2010, 6:195-197.
15. Hicks D.G., Short S.M., Prescott N.L., Tarr S.M., Coleman K.A., Yoder B.J., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006, 30:1097-1104.
16. Ho-Yen C., Bowen R.L., Jones J.L. Characterisation of basal-like breast cancer, an update. Diagn Histopathol 2012, 18:104-111.
17. Hu R., Dawood S., Holmes M.D., Collins L.C., Schnitt S.J., Cole K., et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011, 17:1867-1874.
18. Kuenen-Boumeester V., Van der Kwast T.H., Claassen C.C., Look M.P., Liem G.S., Klijn J.G., et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996, 32:1560-1565.
19. Lacroix M., Toillon R.A., Leclercq G. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004, 11:497-522.
20. Luo X., Shi Y.X., Li Z.M., Jiang W.Q. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 2010, 29:585-590.
21. Moinfar F., Okcu M., Tsybrovskyy O., Regitnig P., Lax S.F., Weybora W., et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003, 98:703-711.
22. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
23. Ogawa Y., Hai E., Matsumoto K., Ikeda K., Tokunaga S., Nagahara H., et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 2008, 13:431-435.
24. Park S., Koo J., Park H.S., Kim J.H., Choi S.Y., Lee J.H., et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010, 21:488-492.
25. Putti T.C., El-Rehim D.M., Rakha E.A., Paish C.E., Lee A.H., Pinder S.E., et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 2005, 18:26-35.
26. Qi J.P., Yang Y.L., Zhu H., Wang J., Jia Y., Liu N., et al. Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients. Breast Cancer 2012, 6:1-8.
27. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
28. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
29. Riva C., Dainese E., Caprara G., Rocca P.C., Massarelli G., Tot T., et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 2005, 447:695-700.
30. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
31. Shim H.S., Jung W.H., Kim H., Park K., Cho N.H. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions. APMIS 2006, 114:352-358.
32. Sobin L.H., Gospodarowicz M.K., Wittekind C. Breast tumours. TNM classification of malignant tumours 2009, 181-194. Wiley-Blackwell, New York. 7th ed. L.H. Sobin, M.K. Gospodarowicz, C. Wittekind (Eds.).
33. Tan D.S., Marchió C., Jones R.L., Savage K., Smith I.E., Dowsett M., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
34. Tan D.S., Marchió C., Jones R.L., Savage K., Smith I.E., Dowsett M., et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008, 111:27-44.
35. van de Rijn M., Perou C.M., Tibshirani R., Haas P., Kallioniemi O., Kononen J., et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002, 161:1991-1996.
36. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.